Medexus Pharmaceuticals Valuation
Is MDP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MDP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MDP (CA$2.15) is trading below our estimate of fair value (CA$83.98)
Significantly Below Fair Value: MDP is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MDP?
Key metric: As MDP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is MDP's PE Ratio? | |
|---|---|
| PE Ratio | 16.5x |
| Earnings | US$2.30m |
| Market Cap | US$37.21m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 3.9x |
| PEG Ratio | 0.3x |
Price to Earnings Ratio vs Peers
How does MDP's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 31.2x | ||
HASH Simply Solventless Concentrates | 63x | n/a | CA$51.3m |
WOLF Grey Wolf Animal Health | 38.9x | n/a | CA$27.3m |
RX BioSyent | 18.3x | n/a | CA$126.5m |
MTLC MTL Cannabis | 4.5x | n/a | CA$20.5m |
MDP Medexus Pharmaceuticals | 16.5x | 49.9% | CA$52.0m |
Price-To-Earnings vs Peers: MDP is good value based on its Price-To-Earnings Ratio (16.5x) compared to the peer average (31.2x).
Price to Earnings Ratio vs Industry
How does MDP's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?
| 17 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 17 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: MDP is good value based on its Price-To-Earnings Ratio (16.5x) compared to the North American Pharmaceuticals industry average (18.5x).
Price to Earnings Ratio vs Fair Ratio
What is MDP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.5x |
| Fair PE Ratio | 29.2x |
Price-To-Earnings vs Fair Ratio: MDP is good value based on its Price-To-Earnings Ratio (16.5x) compared to the estimated Fair Price-To-Earnings Ratio (29.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CA$2.15 | CA$4.44 +106.6% | 41.2% | CA$8.25 | CA$2.60 | n/a | 7 |
| Nov ’25 | CA$2.43 | CA$4.18 +71.8% | 45.6% | CA$8.25 | CA$2.60 | n/a | 6 |
| Oct ’25 | CA$2.58 | CA$4.01 +55.3% | 45.2% | CA$8.25 | CA$2.60 | n/a | 7 |
| Sep ’25 | CA$2.45 | CA$3.30 +34.7% | 17.1% | CA$4.40 | CA$2.60 | n/a | 6 |
| Aug ’25 | CA$2.35 | CA$2.88 +22.7% | 27.1% | CA$4.40 | CA$2.00 | n/a | 6 |
| Jul ’25 | CA$1.82 | CA$2.99 +64.4% | 24.4% | CA$4.40 | CA$2.00 | n/a | 7 |
| Jun ’25 | CA$1.62 | CA$3.21 +98.0% | 39.4% | CA$5.90 | CA$2.00 | n/a | 6 |
| May ’25 | CA$1.75 | CA$3.21 +83.3% | 39.4% | CA$5.90 | CA$2.00 | n/a | 6 |
| Apr ’25 | CA$1.61 | CA$3.25 +101.9% | 42.5% | CA$5.90 | CA$2.00 | n/a | 5 |
| Mar ’25 | CA$1.82 | CA$3.25 +78.6% | 42.5% | CA$5.90 | CA$2.00 | n/a | 5 |
| Feb ’25 | CA$2.34 | CA$4.14 +76.9% | 22.3% | CA$5.90 | CA$3.30 | n/a | 5 |
| Jan ’25 | CA$2.47 | CA$4.08 +65.0% | 21.0% | CA$5.90 | CA$3.30 | n/a | 6 |
| Dec ’24 | CA$1.45 | CA$4.08 +181.0% | 21.0% | CA$5.90 | CA$3.30 | n/a | 6 |
| Nov ’24 | CA$2.02 | CA$4.23 +109.6% | 19.4% | CA$5.90 | CA$3.50 | CA$2.43 | 6 |
| Oct ’24 | CA$3.05 | CA$4.17 +36.6% | 16.5% | CA$5.50 | CA$3.50 | CA$2.58 | 6 |
| Sep ’24 | CA$2.89 | CA$4.17 +44.2% | 16.5% | CA$5.50 | CA$3.50 | CA$2.45 | 6 |
| Aug ’24 | CA$2.17 | CA$3.53 +62.8% | 32.7% | CA$5.50 | CA$1.80 | CA$2.35 | 6 |
| Jul ’24 | CA$1.86 | CA$3.53 +90.0% | 32.7% | CA$5.50 | CA$1.80 | CA$1.82 | 6 |
| Jun ’24 | CA$1.24 | CA$3.30 +166.1% | 41.8% | CA$5.50 | CA$1.50 | CA$1.62 | 6 |
| May ’24 | CA$1.35 | CA$3.30 +144.4% | 41.8% | CA$5.50 | CA$1.50 | CA$1.75 | 6 |
| Apr ’24 | CA$1.60 | CA$3.30 +106.3% | 41.8% | CA$5.50 | CA$1.50 | CA$1.61 | 6 |
| Mar ’24 | CA$1.75 | CA$3.26 +86.3% | 45.2% | CA$5.50 | CA$1.50 | CA$1.82 | 5 |
| Feb ’24 | CA$1.85 | CA$5.00 +170.3% | 65.4% | CA$11.00 | CA$1.50 | CA$2.34 | 5 |
| Jan ’24 | CA$2.08 | CA$5.00 +140.4% | 65.4% | CA$11.00 | CA$1.50 | CA$2.47 | 5 |
| Dec ’23 | CA$2.11 | CA$5.00 +137.0% | 65.4% | CA$11.00 | CA$1.50 | CA$1.45 | 5 |
| Nov ’23 | CA$1.80 | CA$4.50 +150.0% | 79.5% | CA$11.00 | CA$1.00 | CA$2.02 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Fennec Pharmaceuticals
US$117.3m
Operates as a biopharmaceutical company in the United States.
FRX
US$6.50
7D
7.6%
1Y
-44.2%
Verano Holdings
CA$850.9m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$2.32
7D
-12.8%
1Y
-60.6%
Cresco Labs
CA$745.0m
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.
CL
CA$1.67
7D
-16.9%
1Y
-26.8%